Podcasts about nkt

High-voltage electricity cables are in huge demand around the world, so much so that a lack of cabling has become a bottleneck throttling the clean energy transition. So why are cable manufacturers so hesitant to expand? Also, how are these giant cables made? And is China about to eat everyone's lunch? Claes Westerlind, chief executive officer of cable manufacturing company NKT, joins Zero to discuss. This is the third episode in Bottlenecks, a series exploring the lesser known obstacles standing in the way of our electrified future. Explore further: Previous episode in Bloomberg Green’s Bottleneckes series: How a Shortage of Transformers Threatens Electricity Supply There Aren’t Enough Engineers to Meet World’s Growing Hunger for Power Electric Cable Companies Are Making a Killing From Green Energy Zero is a production of Bloomberg Green. Our producer is Oscar Boyd. Special thanks to: Jess Beck, Sommer Saadi, Mohsis Andam and Siobhan Wagner. Thoughts or suggestions? Email us at zeropod@bloomberg.net. For more coverage of climate change and solutions, visit https://www.bloomberg.com/green.See omnystudio.com/listener for privacy information.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über haussierende Börsen, gute Nachrichten von Adidas und die Chancen auf Waffenstillstand in der Ukraine. Außerdem geht es um Adidas, Delivery Hero, Apple, Meta, Amazon, Tesla, Enphase, Chipotle, Goldpreis, SK Hynix, IBM, Newmont, ServiceNow, Siemens, ABB, Prysmian, NKT, CRH, Heidelberg Materials, Wienerberger, Holcim, Konecranes, Kion Akzo Nobel, Air Liquide, BASF, Evonik, Ferrexpo, Kernel, Pekao, PKO Bank, Raiffeisen, Wizz Air, Easyjet, Ryanair, Expat Poland WIG20 ETF (WKN: A2JAHA), MSCI All Country World etwa den SPDR MSCI ACWI ETF (WKN: A1JJTC), Vanguard FTSE All World ETF (WKN: A2PKXG) und Alphabet. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In Tübingen eröffnet am Samstag das neue Kunstmuseum Tübingen (NKT). Das privat finanzierte Museum soll ein „Forum für Kunst und Kultur“ sein, so die Vision der Gründer.

Discord: ⁠https://discord.gg/WVVc7GmKfX ⁠ WEB: ⁠https://www.hidnyugatra.hu⁠ MAIL: ⁠ info@hidnyugatra.hu⁠ Patreon: ⁠www.patreon.com/hidnyugatra⁠ Vegyél nekünk kávét: ⁠buymeacoffee.com/hidnyugatra⁠Amelyben Iphone-t veszünk, okoskodunk és mindent megfejtünkTémák:Hírek Iphone kínlódásom folytatáshttps://www.forbes.com/sites/davidphelan/2025/02/13/iphone-se-4-apple-confirms-new-product-launch-date-just-days-away-release-date/ Hírek Bevezető: A sertések életük során akár hatszor is újra tudják növeszteni a fogaikat. A cél, hogy emberek is képesek legyenek erre. https://hvg.hu/tudomany/20250218_fogak-ujranovesztese-sertesek-kiserlet Tegnap vált Használhatatlanná a Humane eszköze, az összes Ai Pin https://hvg.hu/tudomany/20250219_humane-ai-pin-kudarc-leallas-eladas-hp Kijavítja a diktálós hibát az Apple, amely a „rasszista” szót a „Trump” szóra cserélte https://hvg.hu/tudomany/20250226_apple-iphone-hiba-diktalas-rasszista-trump 7,1 millióra nő Orbán Viktor fizetése márciustól https://444.hu/2025/02/25/ez-az-igazi-repulorajt-714-milliora-no-orban-viktor-fizetese-marciustol Érdekesség: wikitok https://wikitok.net/ Hírek: Végre megjelenhetnek az új akkukémiák a mobilokban is https://www.gsmarena.com/samsung_to_bring_galaxy_s26_with_siliconcarbon_batteries-news-66474.php Sorozat: Reacher S03 https://www.rottentomatoes.com/tv/reacher Film: The Killer's Game 2024 https://www.rottentomatoes.com/m/the_killers_game Sonic the Hedgehog 3 2024 https://www.rottentomatoes.com/m/sonic_the_hedgehog_3

Fredag byder på nogle af de sidste danske regnskaber, nemlig fra NKT og DFDS og senere på dagen opdatering fra de globale indkøbschefer. Millionærklubben ser på regnskaberne og taler desuden med NKT’s finansdirektør, Line Fandrup. I studiet giver teknisk analytiker fra Aktierådet, Lars Persson, og chefanalytiker hos Svenssen & Tudborg, Lau Svenssen, deres umiddelbare og gode råd til lytterne, der skriver ind til programmet. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

Bestyrelsesleder i NKT og European Energy, Jens Due Olsen, er ikke i tvivl om hvad der er bestyrelsesarbejdets vigtigste redskab. Nøgleordet er strategi. Vært: Søren Linding, redaktør, kommentator og podcastvært på Finans Gæst: Jens Due Olsen, bestyrelsesleder, NKT m.fl. Podcastredaktør: Kasper Søegaard See omnystudio.com/listener for privacy information.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die Fettweg-Enttäuschung bei Amgen, süße Gewinne für JM Smucker und klingelnde Kassen bei Novo Nordisk und Eli Lilly. Außerdem geht es um Bayer, Cooper Companies, Johnson&Johnson, Alcon, Crowdstrike, Workday, Dell, Rigetti, Quantum Computing, D-Wave Quantum, Coinbase, General Motors, Stellantis, Ford, Assa Abloy, Signify, Volkswagen, Mercedes, BMW, Legrand, Schneider Electric, Siemens, Nibe, SKF, NKT, Atlas Copco, Volvo, Metso, Daimler Trucks und ishares S&P Small Cap 600 (WKN A0Q1YY), Xtrackers Russel 2000 (WKN: A1XEJT). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Der er gang i den på finansmarkederne i øjeblikket.  Donald Trump og republikanerne ser ud til også at tage magten i Kongressen, og dermed lave et såkaldt trifecta. Hvordan det kommer til at påvirke markederne, vender Millionærklubben blandt andet i dagens udsendelse.  Derudover er der landet et par spændende regnskaber - blandt andet fra dansk NKT og allergiselskabet ALK-Abelló. Vi vender begge regnskaber og har blandt andet finansdirektør Line Fandrup fra NKT med på en telefon.  Derudover vender vi de seneste udviklinger på fedmemarkedet, hvor der blandt andet er landet friske data fra det danske biotekselskab Gubra. Vi kigger på interessante muligheder og hører om seneste nyt fra konferencen Obesity Week i USA. Med i studiet er nemlig Gustav Gram fra biotekselskabet Pila Pharma, der var med til konferencen.  Vært: Adam Geil See omnystudio.com/listener for privacy information.

In der Tübinger Schaffhausenstraße entsteht derzeit das Neue Kunstmuseum Tübingen, kurz NKT. Beim Richtfest gab es jetzt nicht nur einen Einblick ins Gebäude, sondern auch in das, was das Publikum dort ab März 2025 erwartet. | Videos in der RTF1 Mediathek: www.rtf1.tv | RTF1 - Wissen was hier los ist! |

In this episode of the Sound of Green podcast, we explore the potential of increased grid and market interconnectivity through the case of Viking Link: the world's longest power cable connecting the UK and Denmark. Listen to the episode and get insights from key actors such as Michael C. Hjorth, Chief Commercial Officer at NKT,  Kristoffer Böttzauw, Director of the Danish Energy Agency and Rebecca Sedler, Managing Director of Interconnectors at the UK energy company National Grid. How do you create an energy supply that is both green, affordable and secure all at the same? As the geopolitical events of the past few years have shown, it is an ideal that's difficult to uphold. However, those same events have also made it clear that we can't let the flow of renewable energy be constrained by borders if we want to see the green energy transition through. To be sure, distributing energy across borders and connecting both grids and markets requires a complex level of collaboration – one that Denmark has long succeeded in.For more information and case material on interconnectors: https://stateofgreen.com/en/focus-areas/energy-distribution-and-integration/

This week, I chatted with David Weinstock, the brilliant mind behind Neurokinetic Therapy (NKT). We dive into the fascinating journey of how NKT came to be, how it's integrated into movement professions like Pilates, and why understanding proper breathing and diaphragm function is so crucial. We also talk in-depth about the role of the psoas muscle in core stability and why it's important to assess whether it's overworking or underworking before diving into treatment. David shares his knowledge on how the psoas connect with other muscles and systems in the body, such as the diaphragm and the limbic system. We also touch on the emotional side of things—how trauma impacts movement—and how addressing this can be key to successful outcomes. David's take on failure and how it's a vital part of learning really resonated with me, as well as his perspective on the joy and reward that comes from helping others and making a positive impact. Takeaways: Neurokinetic Therapy (NKT) is an amazing system that focuses on how movement patterns connect, using biomechanics and neuroscience to assess and rehabilitate both acute and chronic injuries. NKT Meets Pilates: NKT is a perfect complement to Pilates, helping to spot and correct compensatory movement patterns and ensure optimal movement quality. The Importance of Proper Breathing: David talks about how breathing needs to involve a 360-degree expansion of the ribcage (yes, all around!) for the diaphragm to function at its best and how this affects core stability. Psoas Muscle Misunderstandings: The psoas is such an important part of the core, but often misunderstood. Stretching may not be the answer; instead, we need to figure out if it's underworking or overworking before deciding on any treatment. Body Interconnectedness: Every part of the body is connected, and understanding this is essential for effective movement therapy. The psoas, diaphragm, and even the limbic system all work together in fascinating ways. Emotional Trauma's Role: Trauma doesn't just affect the mind; it affects movement. Addressing the limbic system is crucial for deeper healing and more effective treatment. Embracing Failure: David's insight into failure was refreshing—it's a necessary part of learning and growth, something I think we can all relate to. The Reward of Helping Others: David reminds us of the deep fulfillment that comes from helping people heal and make positive changes in their lives. About David Weinstock: David has been at the forefront of manual therapy since 1973, after graduating from Johns Hopkins and traveling throughout Central and South America, learning from native healers. He co-founded the Institute of Conscious Bodywork in California and developed NeuroKinetic Therapy® in 1985. His book, "NeuroKinetic Therapy, an Innovative Approach to Manual Muscle Testing," has become an essential read for anyone in the bodywork field. He teaches internationally, sharing his knowledge with Pilates instructors, chiropractors, physical therapists, and many others. David also runs a private practice in Marin County, where he treats everyone from athletes to weekend warriors, offering personalized treatments to help them recover and thrive. In his free time, David enjoys hiking, skiing, and playing tennis, and he loves connecting with people from around the world, always sharing knowledge and learning from others. Join us for this inspiring conversation to learn how Neurokinetic Therapy can transform the way we approach movement and healing.   Connect With David Weinstock Facebook: https://www.facebook.com/NeuroKineticTherapy/ Instagram: https://www.instagram.com/neurokinetictherapy/ Take Advantage of our Special Offers! Claim it now here: https://www.thepilatesprofessional.com.au/free-gift-workshop   Unlock Your Pilates Potential!  Take This FREE 60-second Quiz To Find Out ”What's your Pilates Personality? https://go2.bucketquizzes.com/sf/75440977   Subscribe to our biweekly Pilates Muse newsletter for exclusive updates. https://www.thepilatesprofessional.com.au/the-pilates-muse-publication  

Det er ikke lang tid siden aktiemarkedet meldte om bål og brand i særligt amerikansk økonomi, men her midt i august er humøret tilsyneladende retur blandt investorerne. Millionærklubben dissekerer stemningen, tager imod dagens aktuelle regnskaber fra bl.a. NKT og Boozt og svarer på lytterspørgsmål med Lars Persson og Michael Friis Jørgensen i studiet. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

From the American Association of Immunologists 2024 conference in Chicago, Cindy and Brianne meet up with Tonya Webb to talk about her career, the role of NKT cells in cancer, and her efforts to ensure diversity, equity, and inclusion in research. Hosts: Cindy Leifer and Brianne Barker Guest: Tonya Webb Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Content in this podcast should not be construed as medical advice.

Der er flere regnskaber på banen onsdag morgen, som byder på tal fra bl.a NKT, DFDS og Bavarian Nordic. Millionærklubben tager temperaturen på nogle af udmeldingerne og taler desuden med NKT's CFO, Line Fandrup om dagens kvartalsmelding. Sidst i udsendelsen er der fokus på Apples seneste produktudmeldinger, når klubbens porteføljeforvalter Anders Bæk leverer en stemningsrapport fra tech-land, og i studiet har aktiechef Micael Friis Jørgensen fra HC Andersen Capital fingeren på onsdagens aktiepuls. Vært: Bodil Johanne Gantzel.  Producer: Kasper RiisingSee omnystudio.com/listener for privacy information.

I Danmark finner vi en rekke spennende børsnoterte selskaper som er godt posisjonert innen vind- og vann. Audun Wickstrand Iversen og Kristine Alm Karsrud, to av forvalterne fra fondet DNB Future Waves, var nylig i København for å møte et knippe av disse selskapene.I denne episoden blir du oppdatert på selskapene de møtte og utsiktene for markedene de opererer i. I tillegg får du høre mer om hvorfor de mener vann er en «utappet» investeringsmulighet.Episoden ble spilt inn mandag 4. mars 2024. Selskapene som omtales er Ørsted, Vestas, NKT, Aquaporin, Novo Nordisk, Maersk og M West Water.Programleder: Marius Brun Haugen, DNB Wealth Management Investment OfficeProdusent: Kim A. Farago, DNB Wealth Management Investment Office Hosted on Acast. See acast.com/privacy for more information.

Pancreatic ductal adenocarcinoma (PDA), a common type of pancreatic cancer, has proven to be largely resistant to immunotherapy, a treatment that uses the body's immune system to fight cancer. Despite numerous successful pre-clinical trials using sophisticated PDA mouse models, clinical trials have failed to show a significant improvement in survival. In a recent editorial, researchers Brian Diskin, Sarah Schwartz and George Miller from Trinity Health of New England shed light on the complex interplay between the immune system and pancreatic cancer. Their paper was published in Oncotarget on April 24, 2023, and entitled, “The critical immune basis for differential responses to immunotherapy in primary versus metastatic pancreatic cancer.” Tumor Microenvironment and Liver Metastasis: Challenges in Pancreatic Cancer The authors attribute PDA immunotherapy resistance to the unique characteristics of the tumor microenvironment (TME). The TME is often hypoxic and fibrotic, making it inaccessible to immune cells. Furthermore, the immune cells that do infiltrate the TME often have tolerogenic features, meaning they are more likely to tolerate the presence of cancer cells rather than attack them. PDA most commonly metastasizes to the liver, an organ known for its immune tolerance. The liver is home to a diverse array of innate immune populations, including NK cells, Kupfer cells, NKT cells, and double negative T cells. Despite this, the liver is the most common location for metastasis from gastrointestinal cancers. “It is an unfortunate fact that all failed clinical trials assessing immunotherapeutic efficacy were conducted in metastatic PDA, whereas basic preclinical investigations are usually performed in primary PDA using genetically engineered mouse models. We postulated that this dichotomy may explain the gap between preclinical promise and ultimate clinical failure.” Full blog - https://www.oncotarget.org/2023/11/16/immunotherapy-response-in-primary-vs-metastatic-pancreatic-cancer/ Paper DOI - https://doi.org/10.18632/oncotarget.28373 Correspondence to - George Miller - gedalyamil@gmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28373 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, pancreatic cancer, liver metastasis, immunnotherapy About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Onsdag byder på masser af friske tal fra de danske børsnoterede selskaber, og Millionærklubbens faste paneldeltager, Michael Friis Jørgensen fra HC Andersen Capital, står klar til analyse og debat om udmeldingerne. Med på telefonen er også Michael Nass Nielsen fra NKT, der har lagt tal på bordet her til morgen. Og fra egne rækker også nyt fra porteføljeforvalter Mads Chistiansen, der leverer en ugentlig opdatering om aktier, han pt. holder øje med. Vært: Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

I mere end et århundrede har NKT leveret kabler til elnettet. Men selvom fødselsattesten er af ældre dato, så har NKT et skarpt blik på fremtiden og er med til at løse en af nutidens største udfordringer: den grønne omstilling. Millionærklubben taler i løbet af efteråret og vinteren med 10 topchefer fra dansk erhvervsliv i vores særudgave "Millionærklubben CEO", som udkommer hver fredag. Det første afsnit zoomer ind på kabelproducenten NKT, hvor Michael Hjorth, kommerciel direktør i NKT, giver et indblik i den 125-årige virksomhed, som gennem tiden har lavet meget andet end blot kabler. Men nu er fokus snævret ind, og NKT fokuserer benhårdt på at levere kabler, som er en essentiel brik i den grønne omstilling. Dog kæmper virksomheden også mod luftige skåltaler fra politikere og et par konkurrenter i udlandet. Vært: Signe TerpSee omnystudio.com/listener for privacy information.

Ready to unlock the secrets of your body, maximize your fitness potential, and rediscover the joy of good old movie nights? Join us on a one-of-a-kind podcast episode where we share some quirky moments from our fitness journey. Think scorpions, cheat days, and horror movies! We're also planning to launch a TikTok channel to review food, promising to be the worst (or maybe the best) food critics you've ever seen. Plus, we discuss the grand opening of a new NKT specialist clinic. Ever wondered how to train for what you want? Let's bust the myth of volume training and shine the spotlight on intensity and programming. Blindly following random apps or workouts may not take you far. It's about having specific goals and finding the right coach or doing your research to achieve them. From understanding the body's complexity to how integral functional medicine, hormones, and gut health are for your body composition, we've got you covered. But that's not all. We dive into the often overlooked mental health aspect of functional medicine. Discover how your headaches, autoimmune diseases, and other physical ailments may be traced back to a lack of replenishment of the body with essential vitamins and minerals. We encourage you to open your minds to a different approach to health. With laughs, insights, and tips from our fitness journey, we're here to help you navigate the world of health, fitness and everything in between. Buckle up, and let's get started!Follow us on IG:@leos_ftiness_adventure@StephmoralessfitApply for 1:1 coaching and get the results you are looking for: https://www.valhalla-athletics.com Join our free Facebook group: https://m.facebook.com/groups/804195770472212/?ref=group_browseBuy our apparel: Valhalla-athleticsapperal.com

In this episode of the Brawn Body Health and Fitness Podcast, Dan is joined by Joel Smith to discuss Training Philosophies for Acceleration, Deceleration, and Change of Direction. Joel Smith is the founder of Just Fly Sports and trains athletes and clients in partnership with Evolutionary Fitness in Cincinnati, Ohio. Joel hosts the Just Fly Performance Podcast, has authored several books on athletic performance, and trains numerous clients in the in-person and online space. Joel was formerly a strength coach for 8 years at UC Berkeley, working with the Swim teams and post-graduate professional swimmers, as well as tennis, water polo, and track and field. A track coach of 11 years, Joel coached for the Diablo Valley Track and Field Club for 7 years, and also has 6 years of experience coaching sprints, jumps, hurdles, pole vault and multi-events on the collegiate level, working at Wilmington College, and the University of Wisconsin, LaCrosse. Joel has coached 2 national champions, multiple All-Americans and school record holders in his time as a track coach. In the realm of strength and conditioning, his programs have assisted 5 athletes to Olympic berths that produced 9 medals and a world record performance at Rio in 2016. In 2011, Joel began Just Fly Sports as a central platform to promote information for athletes and coaches to reach their highest potential. In 2016 the first episode of the “Just Fly Performance Podcast” was released, now a leading source of education in the sports performance field. The evolving mission of Just Fly Sports is focused on teaching athletes to realize their true, innate power, and achieve the highest joy in their training, competition, and in the community. Joel has also spent several years in the realms of college lecturing, personal training, and thesis research. Joel's certifications include Neurological and Physical Typing from BATI, CSCS, MAT Jumpstart, and NKT level 1, as well as USA Track and Field credentials. Joel is also well-versed in the Be-Activated protocols as taught by Douglas Heel, Foot training and biomechanical concepts from Gary Ward, and has been extensively mentored by sprint and sport movement coach Adarian Barr. For more on Joel and Just Fly Performance, be sure to check out just-fly-sports.com & @justflysports To keep up to date with everything Dan is doing on the podcast, be sure to subscribe and follow @brawnbody on social media! Episode Sponsors: MoboBoard: BRAWNBODY10 saves 10% at checkout! AliRx: DBraunRx = 20% off at checkout! https://alirx.health/ MedBridge: https://www.medbridgeeducation.com/brawn-body-training or Coupon Code "BRAWN" for 40% off your annual subscription! CTM Band: https://ctm.band/collections/ctm-band coupon code "BRAWN10" = 10% off! PurMotion: "brawn" = 10% off!! TRX: trxtraining.com coupon code "TRX15BRAWN" = 15% off GOT ROM: https://www.gotrom.com/a/3083/5X9xTi8k Red Light Therapy through Hooga Health: hoogahealth.com coupon code "brawn" = 12% off Ice shaker affiliate link: https://www.iceshaker.com?sca_ref=1520881.zOJLysQzKe Training Mask: "BRAWN" = 20% off at checkout https://www.trainingmask.com?sca_ref=2486863.iestbx9x1n Make sure you SHARE this episode with a friend who could benefit from the information we shared! Check out everything Dan is up to, including blog posts, fitness programs, and more by clicking here: https://linktr.ee/brawnbodytraining Liked this episode? Leave a 5-star review on your favorite podcast platform! --- Send in a voice message: https://podcasters.spotify.com/pod/show/daniel-braun/message Support this podcast: https://podcasters.spotify.com/pod/show/daniel-braun/support

Dagens erhvervsoverblik: Wagner-leder Prigozjin er død. Mærsk bekræfter at havnearbejdere har forbindelse til Hells Angels. Japanere gør nyt forsøg på at købe NKT-selskab. Ifølge tænketank skal råderum opjusteres igen – er op mod 10 mia. kr. større. Nvidia overrasker igen positivt. Vært: Lasse Ladefoged (lala@borsen.dk)

Efter et par negative børsdage tyder noget på, at vinden igen er ved at vende. Millionærklubben ser på sagen, dykker ned i dagens regnskabstal fra A. P. Møller - Mærsk og svarer på spørgsmål fra lytterne. Du kan høre mere om blandt andre Bavarian Nordic, Betsson, NKT, Brdr. Hartmann, Lundbeck, Bravida, Concordia Maritime, Norwegian, DNO, Aker BP, Vår Energi og Okea og ISS I studiet: Lau Svenssen, Lars Persson og Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

Et ord bliver centrum i dagens udsendelsen: Aktieinspiration. Millionærklubben får nemlig besøg af Thorleif Jackson, direktør i Jackson Familieinvest, og Per Juul, direktør i Juul Value Invest, som hver især har taget en håndfuld aktier med, som de finder interessante. Lars Persson, Millionærklubbens faste forvalter, guider os gennem dagens marked.Vært: Signe Terp Du kan i dagens afsnit blandt andet høre om aktierne: Apple, Alphabet, TAG Immobilien, Leg Immobilien, PayPal, Cigna, Pandora, Deutsche Wohnen, Balder, Walgreens Boots Alliance, NKT, Bavarian Nordic, Novo Nordisk og Vonovia.See omnystudio.com/listener for privacy information.

Join hosts Gary Deagle and Will Shively of Coastal Strength & Fitness and Fit For Life Radio in a conversation with Ben Lengel, a Coastal coach, NKT practitioner, and Pro Disc Golf athlete. In this episode, we delve into the world of Ben's multifaceted journey. We explore Ben's personal workout routine, where he shares valuable insights on how strength training not only complements his passion for Disc Golf but also supports his overall well-being. Discover how Ben rekindled his love for Disc Golf after a long hiatus and its profound impact on his life. As a NeuroKinetic Therapy (NKT) practitioner, Ben sheds light on the power of this innovative practice. Gain a deeper understanding of how NKT enhances movement patterns, promotes balance, and helps athletes optimize their performance. We also explore Ben's dietary approach, learning about his nutrition strategies to fuel his active lifestyle and maintain peak performance. Get an inside look at how Ben balances the various facets of his life. From being a dedicated coach at Coastal Strength & Fitness to fulfilling his roles as a loving husband, and stepdad, discover the secrets to his ability to find harmony and fulfillment in his pursuits. Whether you're a client at Coastal Strength & Fitness, fitness enthusiast, Disc Golf aficionado, or simply seeking inspiration for balancing work, life, and passion, this episode is sure to provide valuable insights and motivate you on your own journey toward a fit and fulfilled life.

Regnskabssæsonen står for døren, og vi har allerede fået de første opjusteringer fra blandt andre en række banker og Novo Nordisk. Samtidigt er der igen god stemning på aktiemarkedet, med flotte stigninger i både USA og Europa. Klubbens egne forvaltere Lars Persson og Lau Svenssen er i studiet for at vende de seneste tendenser og tage imod spørgsmål fra lytterne. Du kan høre mere om blandt andet medicinalselskabet Novo Nordisk, bilproducenten Volvo, Danske Bank, flyselskabet SAS, høreapparatkoncernen GN Store Nord, fragtselskabet DSV og industriselskaberne Lundin Mining og FLSmidth og allergimedicinproducenten ALK samt Trelleborg. Du kan også høre om vaccineproducenten Bavarian Nordic, kabelproducenten NKT samt rederiet Mærsk og  Ericsson. Vært: Sara SjølinSee omnystudio.com/listener for privacy information.

Millionærklubben tager hul på sidste børsdag i ugen og klubbens to forvaltere, Lau Svenssen og Lars Persson, svarer på spørgsmål fra lytterne. Med på telefonen er også Jens Bjerg Sørensen, CEO i Schouw & Co., med en kommentar til dagens aktuelle regnskabstal og selskabets syn på fremtiden. Vært: Bodil Johanne Gantzel.  I dagens afsnit kan du høre om følgende aktier: NKT, Subsea 7, Rockwool, Novozymes, Elekta, Arjo, Nokia, Tesla, Norden, Genmab, Shell, Evolution Gaming, H+H  og Nobia.See omnystudio.com/listener for privacy information.

Spritnye ordretal fra cement- og mineudstyrsgiganten FLSmidth lever ikke op til investorernes forventninger, og heller ikke NKT synes at brillere onsdag morgen, hvor selskabets guidence er meldt ud til den skuffende side. Millionærklubben tager temperaturen på de to aktiers kursudvikling og taler med CFO i FLS, Roland Andersen. Med i studiet er Henrik Karlsen, disruption- og innovationsspecialist, fra fonden Horizon3, der går benhårdt efter compounder-aktier i tech-miljøet. Dagens marked serveres af klubbens porteføljeforvalter, Michael Friis Jørgensen, med Bodil Johanne Gantzel ved roret som vært. See omnystudio.com/listener for privacy information.

In today's episode, Brittny chats with Dr. Perry Nickelston, DC, NKT, FMS, SFMA of  Stop Chasing Pain, LLC. Dr. Perry aka ‘The Lymph Doc' is a Chiropractic Physician with a primary focus on treating chronic pain and inflammation via the lymphatic and vascular systems. He is a international speaker and educator of the self-care MOJO series-Lymphatic Mojo, Blood Flow Mojo, Tongue Mojo, Glymphatic Mojo, Visceral Mojo, Vagus Nerve Mojo, Primal Movement Mojo.Dr. Perry is an expert in movement assessment and diagnosis. Certified and trained as a Functional Movement Specialist (FMS) and Selective Functional Movement Assessment Specialist (SFMA). He uses programs designed to find sources of non-painful dysfunction so your site of pain improves.After healing from a severe back injury and autoimmune disease he decided to dedicate himself to offering these self-care approaches to others. Designer of the Body Ecosystem Hierarchy is a self-treatment program whose sole purpose is to empower you to regain control of your life from chronic pain.

In this last episode of the year, Greg and Adam review some recent literature on spontaneous ACL healing, the cult that is NKT and some promising signs for 2023. To find out about Rehab Guru click here To become a NAF Podcast Patreon click here

Charles Clay interacts with the world from a grounded, holistic perspective. But, his confidence was not always as strong as it is today. Though Charles grew up in picturesque rural Washington, his childhood wasn't a fairytale. Clay's parents divorced when he was four years old. This trauma colored his future beliefs on nearly everything: confidence, purpose, money, and career. It took another trauma, a skiing accident in 2008, for Charles to face his inherited internal blockers. While suffering from back pain after his accident, Charles discovered NeuroKinetic Therapy®, or NKT. Inspired by the teachings from NKT, Clay created new programs – The InnerPeace Process and The Laser Focus Method – that he uses with his clients today.  Pain can serve as a powerful indicator in our bodies and our minds, like a check engine light alerting us that something is not quite right. Charles believes that we often overlook the messages that our bodies send us. He implements The InnerPeace Process with his clients to unlock the root cause of their unease and help free them from it. Often, physical pain shows up as a symptom of unresolved emotional problems under the surface: anger, stress, and resentment.  Charles challenges you to ask: what is my body telling me? And what should I do about it? From his experience, Charles knows that when you're aligned with your emotions, existing patterns are challenged. After his parents' divorce, he inherited two money mindsets. From his dad, that money was a roller coaster. From his mom, there was never enough money to go around. Understanding the origin of his money mindset allowed Charles to own his past patterns and gave him a boost to create a new future for his finances.  On this episode of Money Loves Women, join Dr. Deborah Ekstrom and Charles Clay to learn about the power of uncovering the root cause of our pain, and unlearning and reshaping our money mindsets. Topics Discussed: Pain Money mindsets Resolving difficult emotions NeuroKinetic Therapy® The InnerPeace Process Abundance Resources:  Charles Clay's Instagram, @charlesclay.coach  Charles Clay's Coaching Website NeuroKinetic Therapy - by David Weinstock Charles Clay's LinkedIn For more information on how to achieve financial freedom, personal mastery, and professional success, please visit https://moneyloveswomen.com/.   

Vanen tro åbner Millionærklubben hanerne for spørgsmål fra lytterne. Du kan sende dit spørgsmål allerede nu på sms 42 42 03 21 og start beskeden med “MIO”. I dagens panel sidder d'herrer Lars Persson, teknisk analytiker, og den erfarne fundamental analytiker Lau Svenssen klar til at svare på spørgsmål. Du kan høre mere om blandt andre: Mærsk, DFDS, NKT, Royal Unibrew, Anheuser-Busch, Vestas, Siemens Energy, Novo Nordisk, ALK-Abelló, Ambu, AstraZeneca, Volkswagen, Toyota, Continental, NKT, KION, Fluoguide. Din vært i dag: Simon Richard Nielsen.See omnystudio.com/listener for privacy information.

2022 har været et rigtig skodår, og 2023 kan næsten kun blive bedre. Jakob Vejlø, chefstrateg hos BankInvest, er i studiet for at fortælle om de tre ting, han tror kan overraske positivt til næste år og skabe bedre stemning på finansmarkedet. Vi har også Per Hansen fra Nordnet med på telefon til en snak om Kåre Schultzs exit fra Teva. Klubbens egen forvalter Lars Persson løber os igennem dagens aktiemarked. Vært: Sara Sjølin.Hør også om ALK-Abelló og NKT. See omnystudio.com/listener for privacy information.

Missilnedslag i Polen tirsdag gav sug i maven på investorerne, men det ser dog ud til at være en kortvarig forskrækkelse. Millionærklubben tager temperaturen på dagens marked og dykker bl.a. ned i regnskabsaktuelle Sea Ltd. med porteføljeforvalterne Mads Christiansen og Michael Friis Jørgensen i studiet. Med på telefonen er også NKT's CFO, Line Fandrup, om dagens regnskab for 3. kvartal. Vært: Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

This month on Episode 41 of Discover CircRes, host Cynthia St. Hilaire highlights four original research articles featured in the September 30 and October 14 issues of Circulation Research. This episode also features an interview with Dr Kory Lavine and Dr Chieh-Yu Lin from Washington University St. Louis, to discuss their study, Transcriptional and Immune Landscape of Cardiac Sarcoidosis.   Article highlights:   Tian, et al. EV-Mediated Heart Brain Communication in CHF   Wleklinski, et al.  Impaired Dynamic SR Ca Buffering Causes AD-CPVT2   Masson, et al. Orai1 Inhibition as a Treatment for PAH   Li, et al. F. Prausnitzii Ameliorates Chronic Kidney Disease   Cindy St. Hilaire:        Hi, and welcome to Discover Circ Res, the podcast of the American Heart Association's journal, Circulation Research. I'm your host, Dr Cynthia St. Hilaire from the Vascular Medicine Institute at the University of Pittsburgh, and today I'm going to highlight articles from our September 30th and October 14th issues of Circulation Research.                                           I'm also going to have a chat with Dr Kory Lavine and Dr Chieh-Yu Lin from Washington University St. Louis, and we're going to discuss their study Transcriptional and Immune Landscape of Cardiac Sarcoidosis. But before I get to the interview, I'm going to highlight a few articles.   Cindy St. Hilaire: The first article I'm going to share is Extracellular Vesicles Regulate Sympathoexcitation by Nrf2 in Heart Failure. The first author of this study is Changhai Tian, and the corresponding author is Irving Zucker, and they are at University of Nebraska. After a myocardial infarction, increased oxidative stress in the heart can contribute to adverse cardiac remodeling, and ultimately, heart failure. Nrf2 is a master activator of antioxidant genes, suggesting a protective role, but studies in rats have shown its expression to be suppressed after MI, likely due to upregulation of Nrf2-targeting microRNAs. These microRNAs can also be packaged into vesicles and released from stressed heart cells.   Now, this group has shown that rats and humans with chronic heart failure have an abundance of these microRNA-containing EVs in their blood. In the rats with chronic heart failure, these extracellular vesicles were found to be taken up by neurons of the rostral ventrolateral medulla, RVLM, wherein the microRNA suppressed Nrf2 expression. The RVLM is a brain region that controls the sympathetic nervous system, and in the presence of EVs, it is ramped up by sympathetic excitation. Because such elevated sympathetic activity can induce the fight or flight response, including increased heart rate and blood pressure, this would likely worsen heart failure progression. The team, however, found that inhibiting microRNAs in the extracellular vesicles prevented Nrf2 suppression in the RVLM and sympathetic activation, suggesting the pathway could be targeted therapeutically.   Cindy St. Hilaire:        The next article I want to highlight is titled, Impaired Dynamic Sarcoplasmic Reticulum Calcium Buffering in Autosomal Dominant CPVT2. The first author of this study is Matthew Wleklinski, and the corresponding author is Bjӧrn Knollmann, and they are at Vanderbilt University.   Exercise or emotional stress can prompt the release of catecholamine hormones, which induce a fast heart rate, increased blood pressure, and other features of the fight or flight response. For people with catecholaminergic polymorphic ventricular tachycardia, or CPVT, physical activity or stress can cause potentially lethal arrhythmias. Mutations of calsequestrin-2, or CASQ2, which is a sarcoplasmic reticulum calcium-binding protein, is a major cause of CPVT, and can be recessive or dominant in nature.   For many recessive mutations, disease occurs due to loss of CASQ2 protein. This group investigated a dominant lysine to arginine mutation in this protein, and found by contrast, protein levels remain normal. In mice carrying the mutation, not only was the level of CASQ2 comparable to that in control animals, but so, too, was the protein's subcellular localization. The mutation instead interfered with CASQ2's calcium binding or buffering capability within the sarcoplasmic reticulum. The result was that upon catecholamine injection or exercise, the unbound calcium released prematurely from the sarcoplasmic reticulum, triggering spontaneous cell contractions. In uncovering this novel molecular etiology of CPVT, the work provides a basis for studying the consequences of other dominant CASQ2 mutations.   Cindy St. Hilaire:        The next article I want to highlight is from our October 14th issue of Circulation Research, and the title of the article is ORAI1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension. The first author is Bastien Masson, and the corresponding author is Fabrice Antigny, and they're from Inserm in France. In pulmonary arterial hypertension, the arteries of the lungs become progressively obstructed, making it harder for the heart to pump blood through them, ultimately leading to right ventricular hypertrophy and heart failure. A contributing factor in the molecular pathology of pulmonary arterial hypertension is abnormal calcium handling within the pulmonary artery smooth muscle cells. Indeed, excess calcium signaling causes these cells to proliferate, migrate, and become resistant to apoptotic death, thus leading to narrowing of the vessel.   This group now identified the calcium channel ORAI1 as a major culprit behind this excess signaling. Samples of lung tissue from pulmonary arterial hypertension patients and a pulmonary arterial hypertension rat model had significantly upregulated expression of this channel compared with controls. And in patient pulmonary arterial smooth muscle cells, the high ORAI1 levels resulted in heightened calcium influx, heightened proliferation, heightened migration and reduced apoptosis. Inhibition of ORAI1 reversed these effects. Furthermore, in pulmonary hypertension model rats, ORAI1 inhibition reduced right ventricle systolic pressure and attenuated right ventricle hypertrophy when compared with untreated controls. This study indicates that ORAI1 inhibitors could be a new potential target for treating this incurable condition.   Cindy St. Hilaire:        The last article I want to share is titled Faecalibacterium Prausnitzii Attenuates CKD via Butyrate-Renal GPR43 Axis. The first author of this study is Hong-Bao Li, and the corresponding author is Tao Yang, and they are from the University of Toledo.   Progressive renal inflammation and fibrosis accompanied by hypertension are hallmarks of chronic kidney disease, which is an incurable condition affecting a significant chunk of the world's population. Studies indicate that chronic kidney disease is linked to gut dysbiosis. Specifically, depletion of lactobacillus bifidobacterium and faecalibacterium, prompting investigations into the use of probiotics. While supplements including lactobacillus and bifidobacterium have shown little effectiveness in chronic kidney disease, supplementations with F. prausnitzii have not been investigated.   Now, this group has shown in a mouse model of chronic kidney disease that oral administration of F. prausnitzii has beneficial effects on renal function, reducing renal fibrosis and inflammation. This bacterial supplementation also produced the short chain fatty acid butyrate, which was found to be at unusually low levels in the blood samples from the CKD model mice and from chronic kidney disease patients. Oral supplementation with this bacterium boosted butyrate levels in the mice, and in fact, oral administration of butyrate itself mimicked the effects of the bacteria. These findings suggest that supplementation with F. prausnitzii or, indeed, butyrate could be worth investigating as a treatment for chronic kidney disease.   Cindy St. Hilaire:        Today I have with me Dr Kory Lavine and Dr Chieh-Yu Lin from Washington University St. Louis, and we're going to talk about their paper, Transcriptional and Immune Landscape of Cardiac Sarcoidosis. This is in our September 30th issue of Circulation Research. Welcome, and thank you for taking the time to speak with me today.   Chieh-Yu Lin:             Thank you for inviting us. It's a great honor to be here today.   Kory Lavine:               Thank you.   Cindy St. Hilaire:        Really great paper, ton of data, and hopefully, we can pick some of it apart. But before we get into it, I actually want to just talk about sarcoidosis generally. I know it's a systemic inflammatory disease that has this kind of aggregation of immune cells as its culprit, and it can happen in a bunch of different organs. It's mostly in the lung, but it's also, like you're studying, in the heart. Can you just give us a little bit of background? What is sarcoidosis, and how common is cardiac sarcoidosis?   Chieh-Yu Lin:             Well, this is actually a great question, and I'll try to answer it. You actually capture one of the most important kind of features for sarcoidosis. It happens in all kind of organ system, mostly commonly in lung, in lymph nodes, but also in heart, spleen, even in brain, or even orbit, like eyes. It's really a truly multisystemic disease that has been characterized by this aggregate of macrophages, or myeloid cells, with scattered multinucleated giant cells, as the name implies, have multiple nuclear big, chunky, cells that form an aggregate. That's kind of like a pathognomonic feature for sarcoidosis, whether it's happening in lung, in the heart. When any organ system, a lot of studies has been done, but as of now, a very clear pathogenesis or mechanism has been, I would say, still pretty elusive, or still remain quite unclear, despite all the great effort has been made in this field. The other thing is that a lot of the studies actually focusing on pulmonary sarcoidosis for good reasons. Actually, that's one of the most common manifestations. For cardiac sarcoidosis, although it's only effect in probably, I would say depends on the data, 20% to 30% of the outpatient that with sarcoidosis, with or without lung involvement. It's actually carry a very significant clinical implications as of matter that the presentation of cardiac sarcoidosis can be devastating and sometimes actually fatal. Some of the study actually show that cardiac sarcoidosis actually higher, up to 80%, just because the first presentation's actually, unfortunately, sudden cardiac death. That's why Kory and I, we teamed up. I'm a cardiothoracic pathologist, so in my clinical practice I see specimens and samples from human body, from patient suffer from sarcoidosis, both in lung, lymph node, and heart. Kory is an outstanding heart failure, heart transplant cardiologist, see the other end, which is the patient care. This disease, specifically in heart, its presentation and its pathogens in heart, really attracts our attention.   Cindy St. Hilaire:        Do we know any or some of the potential causes? Why it would start, maybe in a different patient population, but also in the heart versus the lung? Do we know anything about that process?   Kory Lavine:              We know nothing about it. Sarcoid has no known etiology. There's been thoughts in the past that it may be driven by infection, the typical pathogens or autoimmune ideologies, but really, there's little data out there to support those possibilities. Right now, the field's wide open. The other challenge is we don't really have a good way to treat this disease, so a lot of the therapies available are things like steroids, which can have some effect on the disease but carry a lot of risk of complications. The other agents that we sometimes use to lower the doses of steroids, things like methotrexate and azathioprine, are only modestly effective.   These are really the motivation for Chieh-Yu and myself to pursue this. We don't really know what causes the disease, and we don't really have very good treatments. We really wanted to take the first step, that's to study the real disease, and understand what are the pathologic cell types that are present within the granuloma, which is these aggregation of immune cells that Chieh-Yu was speaking about.   Cindy St. Hilaire:        What is actually happening at the beginning of this disease? These granulomas form, and then what is the pathological progression in the heart? What goes on there?   Chieh-Yu Lin:             This is actually another great question that I will say there's not much that has been discovered because, especially in human tissue, every time we have a sample, it's actually a kind of time point. We cannot do a longitudinal study. But in general speaking, very little is known about how it's initiated because it will need to accumulate to a certain disease burden for this to have a clinical symptom sign and be manifested, and then being clinically studied. We do know that in both heart and lung after treatment of progressions, it's usually in, a general speaking, going through a phase from a more proliferative means that it's creating more granulomas, more  inflammatory cell aggregate, to a more fibrotic phase. Means that sometimes you actually see the granuloma start to disappear or dissipate, and then showing this kind of dense collagen and fibrosis. That has been commonly documented in both lung and heart sarcoidosis. The other things is that very difficult to study this disease that we do not have a great animal model, so we cannot use animal model to try to approximate or really study the disease pathogenesis. There are several animal models they try to use microbacteria or infectious agents, and these infectious agents can create morphologically similar granuloma, per se, but just like in human body. For instance, patients suffer from TB in their lung, biopsy will show this. But clinically, these are two very distinct disease entities, even though they look alike. Even in the heart, one of the conditions that we study in our paper is giant cell myocarditis, as the name implying having multinucleated giant cells granuloma. It looks really alike under microscopy for pathologists like me, but their clinical course in response to treatment is drastically different. This type of barriers and in the current limitations of our study tool makes, as Kory just said, this is really a wide open. We just know so little despite all the effort.   Cindy St. Hilaire:        Yeah. I'm guessing based on this granuloma information, to start with, the obvious question you went after is going after the immune cell populations that possibly contribute to sarcoidosis. To do this, because you have the human tissue, you went for single cell transcriptional profiling, which is a great use of the technology. But what biological sources did you use, and how did you go about choosing patient? Because the great thing about single cell is you can do just that, you can look at however many thousands of cells in one patient. But how do you make sure or check that that is broadly seen versus just a co-founding observation in that patient?   Kory Lavine:               We use explanted hearts and heart tissue from patients that underwent either heart transplantation or implementation of LVADs. It's a pretty big hunk of myocardium, and we're lucky to work with outstanding pathologists both at WashU, JU, as well as our collaborators at Duke. Between the two institutions, we're able to pull together a collection of tissues where we knew there were granulomas within that piece of tissue we analyzed. You bring up an important challenge. You need to make sure the disease and cause of the disease is present in the tissue that you're analyzing, otherwise you'll not come up with the data that really is informative.   Chieh-Yu Lin:             Kory beautifully answered the question, but I just wanted to add one little thing, and that's also why we use various different modalities. Some of them is more inside you, like the NanoString Technologies' spatial transcriptomic. You can visualize and confirm that we are studying the phenomenon that has been described for sarcoidosis, and then using multichannel immunofluorescence to validate our sequencing data, to complement such limitations of certain technology.   Cindy St. Hilaire:        Especially, I feel like with this diseased tissue that it's such a large tissue, there's so much information, it's really hard to dig in and figure out where the signal is. This was a wonderful paper for kind of highlighting, integrating all these new technologies with also just classical staining. Makes for great pictures as well. How does this cellular landscape of cardiac sarcoidosis compare to a normal heart? What'd you find?   Chieh-Yu Lin:             This is a great question. Compared to normal heart, we have been talking about this accumulation of macrophages with scattered multinucleated giant cells. For the similar landscape, first and foremost, you do not see those type of accumulations in brain microscopy or by myeloid markers in the heart. Although, indeed, in even normal heart tissue we have rest and macrophages. It just doesn't form such morphological alterations. But then we dive deep into it, and then we found that from a different cell type perspective, we realized that the granuloma is composed by several different type of inflammatory cells, with most of the T cells and NKT cells kind of adding periphery. The myeloid cells, including the multinucleated giant cells also, are kind of in the center of the granuloma of the sarcoidosis. Then, we further dive in and realize that there are at least six different subtype of myeloid cells that is contributing to the formation of this very eye-catching distinctive granular malformations, and to just never feel first off and foremost, of course, is those multinucleated giant cells that is really distinct, even on the line microscopy] routine change stand.   And then we have a typical monocyte that's more like a precursor being recently recruited to the heart, and we finally sent the other four different type of myeloid cell that carry different markers, and then improving the resident macrophages. Especially for me as a pathologist, I'm using my eye and looking at stand every day, is actually these six type of cells, myeloid cells, actually form a very beautiful special kind of distribution with the connections or special arrangement with all different type, kind of like multinucleated giant cell in the middle, flanked by HLA-DR positive epithelioid macrophages, kind of scatter, and then with dendritic cells and a typical monocyte at the peripheral, and then resident macrophage kind of like in the mix of the seas of granuloma information. All these are distinct from normal heart tissues that does carry a certain amount of macrophages, but just don't form this orchestrated architectural distinct structure that's composed of this very complicated landscape.   Cindy St. Hilaire:        Those images, I think it was figure six, it's just gorgeous to look at, the model you made. One of the questions I was thinking is there must be a significance between these cells that are on the periphery and those that are in the center of this granuloma. Do you have an idea or can we speculate as to are some more cause and some more consequence of the granuloma? Were you able to capture any more information about maybe the initiating steps of these from your study?   Kory Lavine:              That's a great question, and a question the field has had for a long time. Now, we know there's different populations of cells. The single cell data allows us to understand what are the transcriptional differences and distinctions between them to gain some insights. One thing that we do know from the field is that disease activity correlates with mTOR activity within these granulomas. We took advantage of phospho-S6 kinase staining as a downstream marker of mTOR activity, and Ki-67 is a marker of self proliferation.   Which of these populations within the granuloma might be most active with respect to mTOR and respect to proliferation? If you ask most people in the field, they would jump up and say, "It's the giant cell in the middle." We found that that's not actually the case at all. It's the macrophages that surround the giant cell, the ones that are HLA-DR positive, the epithelioid macrophages, and the ones that are SYLT-3 positive that are scattered around them. That's really interesting and could make a lot of sense, and leads to hypothesis that perhaps activation mTOR signaling within certain parts of the granuloma might be sufficient to set up the rest of the architecture. That's something that we can explore in animal models, and are doing so to try to create a cause and effect relationship. Cindy St. Hilaire:        Yeah, and I was actually thinking about this, too, in relation to kind of the resident macrophages versus infiltrating macrophages or even just infiltrating immune cells. Do you know the original source of the cells that make up the granuloma? Is it mostly resident immune, or are they recruited in?   Kory Lavine:               We can make predictions from the single cell data where you can use trajectory analysis to make strong predictions about what the origin of different populations might be. What those analyses predicted is that the giant cells and the cells that surround the giant cells, the HLA-DR positive and SYLT-3 positive macrophages, come from monocytes. That's the prediction, and, of course, resident macrophages do not. However, that prediction has to be tested, and that's the beauty and importance of developing animal models. The wonderful thing today is we now have genetic tools to do that. We can ask that question.   Cindy St. Hilaire:        I don't know. Maybe you don't want to spoil the lead of the next paper, but what kind of mouse model are you thinking about trying?   Kory Lavine:               Yeah. First of all, let me talk about the tools that are available, because they're published in Circulation Research, of course. We have a nice tool to specifically mark, track and delete in tissue resident macrophages using a CX3CR1 ERT pre-mouse, and taking advantage of the concept that tissue macrophages don't turn over from monocytes and turn over from themselves. We can give tamoxifen to label all monocytes macrophages in Dcs with that CRE, and then wait a period of time where only the resident macrophages remain labeled. We can use that trick to modulate mTOR signaling as a first step, and ask whether mTOR signaling is required in that population. We've now developed a new genetic tool to do the same thing in just recruited macrophages.   Cindy St. Hilaire:        What was the most challenging aspect of this study? There's a lot of moving parts. I'm sure probably the data analysis alone is challenging, but what would you say is the most challenging?   Kory Lavine:               I think you alluded to this early on, but the most challenging thing is collecting the right tissues to analyze, and that's not a small feat or a small effort here. All the technologies are a lot of fun, and everything works so well today compared to many years ago when we trained, so it's an exciting time to do science. The most challenging and time-consuming component was assembling a group of tissues that we could do single-cell sequencing on between our group and our colleagues at Duke, and then creating validation cohorts that we did across several different institutions, including our own as well as Stanford. That team effort in building that team is the most important, challenging, and honestly, enjoyable part of this.   Chieh-Yu Lin:             I cannot agree more what Kory just said. I think that that's the challenging and the fun part, and that we're very fortunate to really have a great team to tackle this questions in multiple from multiple institute. I just want to add one more thing that, particularly for me as a cardiopathologist, one of the hardest things is I've known how to look or diagnose sarcoidosis for years, but seeing the data emerging that is so complicated and then beyond my reliable eyes in understanding, it's kind of mentally very challenging but very fun to really open and broaden the vision. It's not just how it looks like just giant cells in macrophages.   Cindy St. Hilaire:        What do you think about in terms of diagnostics or even potential therapies? How do you think this data that you have now can be leveraged towards those objectives, whether it's screening for new cell types that are really key to this granuloma formation versus therapeutically targeting them?   Kory Lavine:              This study opens new doors, and right now, diagnosis of sarcoids islimited by trying to biopsy, which, in the heart, is limited by sample bias. You certainly can biopsy the wrong area because you don't know whether a granuloma is in the area or not. We do do some cardiac and other imaging studies like FDG-PET scans, which are helpful but are not perfect, and each of them has their individual limitations. One of the beauties of our study is it identifies new markers of macrophage populations that live within the granuloma, many of which are unique to this disease.   That suggests that there's maybe an opportunity to develop imaging tracers that can identify those populations more specifically than our current PET imaging studies do, which rely simply on glucose uptake. It also opens up the possibility that we may able to take blood samples and identify some of these cell types within the blood, and have more simple testing for our patients. I think in terms of therapy, you alluded to it earlier, these concepts about mTOR signaling, that could be a new therapeutic avenue that needs to be rigorously explored in preclinical models. We're lucky already to have very good mTOR inhibitors available in clinical practice today.   Cindy St. Hilaire:        Obviously, opening new doors is amazing because it's more information, but often a good study leads to even more questions to be asked. What question, or maybe what questions, are you guys going to go after next?   Chieh-Yu Lin:             Well, that list is very long, and then that's actually the exciting thing about doing this research. There's no bad questions, in some sense. All the way from diagnosis, management, monitoring, therapeutic, how we predict where the patient can respond, that's the whole clinical side. Even the basic science side, we still haven't really answered the question, although our data suggests where that multinucleated giant cells coming from. It's very eye catching. How do they form, even though our data suggests it's from the recruited macrophages. But that's still a long way from the recruited macrophage,  monocyte to that gigantic bag of nuclei in the very fluffy cytoplasm.   And then, how the granuloma, as we discussed earlier in this discussion, really initially from a relatively normal background myocardium to form this disease process. There are just so many questions that we can ask. There are, of course, several fronts that we would like to focus on. Kory already nicely listed some of them. First and foremost is actually to establish animal model to enable us to do more details in mechanistic studies, because human tissue, as good as it is, it's kind of like a snapshot, just one time point, and it really limits our ability to test our hypothesis. Animal model, certainly, is one of the major directions that we are going forward, but also the other side, like more clinical science also to develop novel noninvasive methodologies to diagnose and to hopefully monitor this patient population in a better way.       Cindy St. Hilaire:        Well, it's beautiful work. I was actually reading this paper this weekend at a brunch place just next door to my house, and the guy sitting next to me happened to see over my shoulder the title and said that his father had passed away from it. This is hopefully going to help lots of people in the future, and really help to make the models that we need to ask, "What's happening in this disease?" Thank you so much for taking the time to speak with me, and congratulations on what seems to be a landmark study in understanding what's going on in this disease.   Chieh-Yu Lin:             Thank you so much. It's a pleasure.   Cindy St. Hilaire:        That's it for our highlights from the September 30th and October 14th issues of Circulation Research. Thank you so much for listening. Please check out the Circ Res Facebook page, and follow us on Twitter and Instagram with the handle @CircRes, and hashtag Discover Circ Res. Thank you so much to our guests, Dr Kory Lavine and Dr Chieh-Yu Lin from Washington University St. Louis. This podcast is produced by Ashara Retniyaka, edited by Melissa Stoner, and supported by the editorial team of Circulation Research. Some of the copy texts for highlighted articles was provided by Ruth Williams. I'm your host, Dr Cynthia St. Hilaire, and this is Discover Circ Res, your on-the-go source for the most exciting discoveries in basic cardiovascular research. This program is copyright of the American Heart Association, 2022. The opinions expressed by speakers in this podcast are their own, and not necessarily those of the editors of the American Heart Association. For more information, please visit ahajournals.org.  

- Cả nước hiện có hơn 6,4 triệu người khuyết tật (NKT), nhưng chỉ có gần 32% trong số này nằm trong lực lượng lao động. Thực tế, người khuyết tật rất khó tìm được việc làm phù hợp. Đây là nội dung được thảo luận trong tọa đàm “Quyền làm việc của người khuyết tật - Từ chính sách đến thực tiễn”, do báo Kinh tế & Đô thị, Tổ chức ActionAid Quốc tế tại Việt Nam (AAV) và Quỹ Hỗ trợ chương trình, dự án an sinh xã hội Việt Nam (AFV) tổ chức. Chủ đề : Gỡ rào cản, tiếp cận việc làm, người khuyết tật --- Support this podcast: https://anchor.fm/vov1tintuc/support

Perry Nickelston, DC, NKT, FMS, SFMA, is a Chiropractic Physician with primary focus on Performance Enhancement, Corrective Exercise, and Metabolic Fitness Nutrition and trained from The American College of Addictionology and Compulsive Disorders. He is an expert in myofascial, orthopedic, medical and trigger point soft tissue therapy. A member of the Board of Directors and Medical Staff Advisor for AIMLA (American Institute of Medical Laser Application). Dr. Perry teaches healthcare professionals all over the world how to successfully use Class IV Deep Tissue Laser Therapy in alleviating pain. He is the Director of clinical protocols and training for LiteCure Medical Lasers specializing in Myofascial Laser treatments. Dr. Perry is an expert in movement assessment and diagnosis. Certified and trained as a Functional Movement Specialist (FMS) and Selective Functional Movement Assessment Specialist (SFMA). He uses programs designed to find your source of painful dysfunction and correct it so the site of pain improves. A regular columnist for Dynamic Chiropractic, Practice Insights, Chiropractic Economics, To Your Health Magazine, Advance Physical Therapy, PT on the Net, LiveStrong, StrengthCoach, and other industry publications for health and fitness. • This episode of The Ready State Podcast is brought to you by Momentous, a leading high performance lifestyle company making the best supplements and sports nutrition products for individuals looking to optimize all parts of their lives. For Kelly, the very best part of Momentous Whey Protein is that it doesn't make him nauseous. For Juliet, it just tastes good! Kelly's current jam is to mix a scoop of protein into a coconut probiotic yogurt. Juliet's go-to is mixing Momentous Whey Protein with ice and water and she's all set for her post-workout nutrition. If you want to get in on the Starrett's protein game, go to thereadystate.com/momentous and use code TRS for 20% OFF your first purchase.

Perry Nickelston, DC, NKT, FMS, SFMA, is a Chiropractic Physician with primary focus on Performance Enhancement, Corrective Exercise, and Metabolic Fitness Nutrition and trained fromThe American College of Addictionology and Compulsive Disorders. He is an expert in myofascial, orthopedic, medical and trigger point soft tissue therapy. A member of the Board of Directors and Medical Staff Advisor for AIMLA (American Institute of Medical Laser Application). Dr. Perry teaches healthcare professionals all over the world how to successfully use Class IV Deep Tissue Laser Therapy in alleviating pain. Director of clinical protocols and training for LiteCure Medical Lasers specializing in Myofascial Laser treatments.Dr. Perry is an expert in movement assessment and diagnosis. Certified and trained as a Functional Movement Specialist (FMS) and Selective Functional Movement Assessment Specialist (SFMA). He uses programs designed to find your source of painful dysfunction and correct it the site of pain improves. A regular columnist for Dynamic Chiropractic, Practice Insights, Chiropractic Economics, To Your Health Magazine, Advance Physical Therapy, PT on the Net, LiveStrong, StrengthCoach, and other industry publications for health and fitness.After suffering a severe back injury and recovering with laser therapy, he decided to dedicate himself to offering this amazing treatment modality to others. Creator of the Core 4 RRTT Recovery and Regeneration Program for maximum pain relief. A self treatment program whose sole purpose is to empower you to take back control of your life from chronic pain.He is a 1997 graduate from Palmer Chiropractic University and a master fitness trainer with over 25 years experience in the health industry. Suffering from obesity as a teenager and overcoming all of the emotional strife that accompanies being overweight, Dr. Perry dedicated himself to teaching others how to get in shape and lead a healthy lifestyle. He is currently publishing several books on health, fitness, laser therapy, business success, and self treatment programs from his website.Visit Dr. Perry today to get your unique Core 4 System Evaluation to determine why you are hurting, even after others have tried helping. Hundreds have taken advantage of the Stop Chasing Pain program. Now it's your turn!YOU CAN REACH DR. PERRY HEREALSO mentioned in the podcast: BOOK YOUR DUTCH COMPLETE in home urine test HERE and use coupon code ED25 Support this show http://supporter.acast.com/stuff-your-doctor-should-know. See acast.com/privacy for privacy and opt-out information.

This week's episode of Translating Aging features Robin Mansukhani, CEO and Co-founder of Deciduous Therapeutics, a company that aims to positively impact human healthspan by developing medicines which activate the endogenous immune mechanism responsible for the elimination of senescent cells. Today, Robin shares his insights on how senescent cells develop and how Deciduous Therapeutics eliminates them. Robin begins by explaining what causes the growth of senescent cells. He explains that not all senescent cells are dangerous and discusses the various kinds of these cells. Although senescent cells are prominent in age-related diseases, Robin explains that they are also found in younger people with autoimmune diseases such as juvenile diabetes. He goes on to talk about Deciduous Therapeutics' approach in combating senescent cells by activating the NKT cells. He also shares his thinking about the best directions for human trials. The episode concludes with Robin describing the future of Deciduous Therapeutics, and his focus on impacting people globally in a meaningful way. In this episode, you'll learn how senescence arises, traditional senolytic approaches, and the importance of NKT cells in eliminating these pathogenic celss. Episode Highlights: The origin of senescent cells Why are senescent cells highly pathogenic? Breaking down the different kinds of senescent cells The relationship between senescent cells and age-related diseases Senolytics and senostatics: approaches for getting rid of senescent cells Deciduous Therapeutics' approach What happens when senescent cells overpower NKT cells? The role alpha-galactosyl ceramide on NKT cells The current hurdles Deciduous Therapeutics are trying to overcome How Robin see Deciduous Therapeutics in five years Quotes: “Senescent cells are cells that have been irreversibly damaged, and so they exit the cell cycle.” “It's not about the age of the person. It's more about the biological age of the organ and tissue. So we see senescence, also, in young people.” “If you can take a senescent cell that's pathogenic and make it good again, and make it functional again safely and successfully, that would be very useful.” “The approach here and our mindset going into creating this company was: there's a way that nature intended for this to happen, and it is our job to figure that out.” “Getting the first indication to work means that you'll have a runway to lots of success. But if your first one does not work, in a lot of cases, it might mean the end of the company or the end of the runway because you simply don't get enough funding for multiple clinical trials at once. So it is critical.” Links: Email questions, comments, and feedback to podcast@bioagelabs.com Translating Aging on Twitter:https://twitter.com/BioAgePodcast ( @bioagepodcast) BIOAGE Labs Websitehttps://bioagelabs.com/ ( BIOAGELabs.com) BIOAGE Labs Twitterhttps://twitter.com/bioagelabs?lang=en ( @bioagelabs) BIOAGE Labshttps://www.linkedin.com/company/bioage-labs/ ( LinkedIn) Deciduous Therapeutics Websitehttps://www.deciduoustx.com/ ( DeciduousTx.com)

In this week's episode Dara is joined by David Weinstock the creator of NKT. Hear David's fascinating story of how he became an incredible healer and came to develop this truly life changing protocol. Joined by Rabbi Shlomo Ben Ze'ev we learn the connection between the brain, the body, and the Neshama (soul)YouTube: https://youtu.be/8ia5it_WuTo - - - - -Show notes:- - - - -Holy Health Podcast:Email: Holyhealthpodcast@gmail.comInstagram: @holy_healthpodcastHoly Health Official Podcast:https://www.buzzsprout.com/589555/9876240Holy Health YouTube Account:https://www.youtube.com/channel/UCFhhzXTvjVjXxf-dcUHbO8Q- - - - -This podcast has been edited by 'Joker productions'For more information contact:Email: yjokerproductions@gmail.comYouTube: https://www.youtube.com/channel/UCFhhzXTvjVjXxf-dcUHbO8Q

- Đại hội đại biểu toàn quốc Hội Bảo trợ người khuyết tật và trẻ mồ côi Việt Nam lần thứ VI, nhiệm kỳ 2022-2027 diễn ra sáng nay, với sự tham dự của 345 đại biểu, đại diện cho 566.335 hội viên thuộc 2.908 tổ chức hội thành viên tại Trung ương và địa phương đã về dự Đại hội. Đồng chí Bùi Thị Minh Hoài, Bí thư Trung ương Đảng, Trưởng Ban Dân vận Trung ương tới dự và phát biểu chỉ đạo tại Đại hội. Tác giả : Kim Thanh VOV1 Chủ đề : Hội Bảo trợ NKT và trẻ mồ côi VN --- Support this podcast: https://anchor.fm/vov1tintuc/support

Perry Nickelston, DC, NKT, FMS, SFMA, is a Chiropractic Physician with primary focus on Performance Enhancement, Corrective Exercise, and Metabolic Fitness Nutrition and trained from The American College of Addictionology and Compulsive Disorders. He is an expert in myofascial, orthopedic, medical and trigger point soft tissue therapy. Dr. Perry is an expert in movement assessment and diagnosis. He uses programs designed to find your source of painful dysfunction and correct it as the site of pain improves. He is a 1997 graduate from Palmer Chiropractic University and a master fitness trainer with over 25 years experience in the health industry. Suffering from obesity as a teenager and overcoming all of the emotional strife that accompanies being overweight, Dr. Perry dedicated himself to teaching others how to get in shape and lead a healthy lifestyle. He is currently publishing several books on health, fitness, laser therapy, business success, and self treatment programs from his website.JOIN US AS WE EXPLORE:Perry's story from pain to purpose and why he decided to stop chasing pain.The “king of the immune system” and foundation of chronic pain - the lymphatic system – how it works, why it matters and what you need to do to keep your lymph “tank” clean.The major lymphatic blockage or “choke” points and how to release/clean them and why to NEVER do them in the wrong order.An experts advice on how to maintain your own lymph health at home. Lymphs and essential oils, sunlight, infrared saunas, play, rebounding, exercise and more! Why community is the most underrated part of the healing process.How guilty and shame will leave you chronically inflamed and chronically in pain.Schedule a FREE 15 min discovery call with Steve and let's get started on your journey to thriving: https://bit.ly/3BcTsFwCONTACT:Website - https://www.stopchasingpain.com/about/Podcast - https://www.stopchasingpain.com/podcasts/Instagram - @stopchasingpainMENTIONS:Workshop - https://www.stopchasingpain.com/lymphatic-mojo-events/         Product - https://alchemistoils.comBook - Norman Doidge, “The Brain that Changes Itself”Podcast – Jon Levy, https://www.youtube.com/watch?v=q0bzbZzECJk&t=0sSUPPORT THE SHOW ON PATREON:As much as we love doing it, there are costs involved and any contribution will allow us to keep going and keep finding the best guests in the world to share their health expertise with you. I'd be grateful and feel so blessed by your support: https://www.patreon.com/MadeToThriveShowCONTACT Steve Stavs and join our community:https://www.facebook.com/MadeToThriveZA/     https://www.facebook.com/SteveStavsZA/https://www.instagram.com/stevestavsza/  Send me a WhatsApp to +27 64 871 0308. Disclaimer: Please see the link for our disclaimer policy for all of our videos. https://madetothrive.co.za/terms-and-...

Fredagsstemning i studiet, når Lau Svenssen og Per Hansen svarer på spørgsmål fra lytterne og deler anekdoter ud med rund hånd. Hør bl.a., hvad de mener om B&O, NKT og Norsk Hydro og få Laus vurdering af, hvem Putin egentlig er. Vært: Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

In this episode, Courtenay and Dr. Jonathan discuss the role of taking personal responsibility for one's health and how it integrates into other areas of life. Dr. Jonathan shares his story from struggling C/D-average student to doctorate inspired by his passion for fitness. With large inquiry into the body positivity movement and obesity rates, this conversation sheds light onto the importance of taking care of oneself beyond aesthetics to achieve optimal health and longevity. Dr. Jonathan is a coach, published writer, author, speaker, and professor in Exercise Science and Sports Performance. His work can be found in major publications including Muscle & Performance, Wall Street Journal, Women's Health, and Shape where he specializes in merging the gap between research and coaching. He holds impressive credentials as a PhD, CSCS*D, NSCA-CPT*D, USAW, NKT-2, SNS. Connect with Dr. Jonathan: Website: https://drjmike.com Instagram: @drjmike Twitter: Jonathan Mike   Connect with Dr. Jonathan: Website: https://drjmike.com  Instagram: @drjmike Twitter: Jonathan Mike ————————————————— Follow & Connect with Courtenay: https://www.courtenayturner.com Twitter: Courtenay Turner (@CourtenayTurner) :https://twitter.com/CourtenayTurner?s=20 Instagram: https://instagram.com/kineticcourtz?utm_medium=copy_link   Read some of her articles: https://www.truthmatters.biz   & follow TruthMatters on socials: https://instagram.com/truthmatters.biz?utm_medium=copy_link https://twitter.com/truthmatters_tm?s=21 https://m.facebook.com/Truth-Matters-Always-109260064571710/?tsid=0.9090120437539597&source=result ————————————————— Video Edited By Griffo Productions www.griffoproductions.com ————————————————— ©2021 All Rights Reserved Learn more about your ad choices. Visit megaphone.fm/adchoices

If you're feeling stressed, overwhelmed, or uncertain, and as a result you're trying to mentally power through in response, you need to listen to this.  We all want to feel and perform at our best.  Yet, all of us have had moments where it seems that no matter how hard we try, we're swimming upstream against life's current.  Sometimes we feel as if we are struggling just to stay afloat, never mind move ahead.  I don't know about you but when that happens, I have often used the strategy of buckling down, working harder, longer, basically driving through sheer force of will.  My guest for this episode is Dr. Perry Nickelston.  In our conversation he explains the science behind why this approach might be the opposite of what we need to do, to create the results we want.  When focusing on performance in any area of our life or work, we need to consider our physiology as much as our mindset.  We can work harder, be more disciplined, hustle, and grind.  However, when we find ourselves struggling with any of these characteristics it may not be laziness.  We need to examine how other variables such as chronic stress, uncertainty, loneliness, lack of sleep, movement, poor diet and other things that biologically influence our inner world, may be impacting how we perform in our outer world.  When we fail to appreciate how our environment is impacting brain function, toxicity, inflammation, and a myriad of other biological factors that influence how we feel and perform, it's like driving with one foot firmly down on the accelerator, but the other one steadfast on the brake.  I first met Perry years ago when we were both presenting at Filex in Melbourne.  I was impressed with his holistic view of wellbeing and optimization of human performance.  In this episode he offers a perspective on how aspects of our internal and external environment can have an enormous impact on us.  He then shares simple to use practices to help us feel and perform at our best.  Perry Nickelston, DC, NKT, FMS, SFMA, is a Chiropractic Physician with primary focus on Performance Enhancement, Corrective Exercise, and Metabolic Fitness Nutrition and trained from The American College of Addictionology and Compulsive Disorders. He is an expert in myofascial, orthopedic, medical and trigger point soft tissue therapy. A member of the Board of Directors and Medical Staff Advisor for AIMLA (American Institute of Medical Laser Application). Dr. Perry teaches healthcare professionals all over the world how to successfully use Class IV Deep Tissue Laser Therapy in alleviating pain. Director of clinical protocols and training for LiteCure Medical Lasers specializing in Myofascial Laser treatments.You can find him and other resources at www.stopchasingpain.com

Today on the podcast we welcome Dr Perry Nickelston, a man who's work has profoundly changed my life. He's my teacher, a mentor and the first (and likely only) guy featured on The Live Journal. I'm ok bending my own rules since the techniques I've learned from him are also impacting my clients (mostly women's) lives. Perry Nickelston, DC, NKT, FMS, SFMA, is a Chiropractic Physician with primary focus on Performance Enhancement, Corrective Exercise, and Metabolic Fitness Nutrition and trained fromThe American College of Addictionology and Compulsive Disorders. He is an expert in myofascial, orthopedic, medical and trigger point soft tissue therapy. A member of the Board of Directors and Medical Staff Advisor for AIMLA (American Institute of Medical Laser Application). Dr. Perry teaches healthcare professionals all over the world how to successfully use Class IV Deep Tissue Laser Therapy in alleviating pain. Director of clinical protocols and training for LiteCure Medical Lasers specializing in Myofascial Laser treatments. Learn More About Dr. Perry Nikelston here: @StopChasingPain on Instagram, Stop Chasing Pain Website. -- Are you ready for your transformation? Do you want to feel energized, happy and free? Then let's chat! Schedule a Consultation today. For a full list of my offerings please visit my website PaolaAtlason.live. Are you ready for your transformation? Do you want to feel energized, happy and free? Then let's chat! Schedule a Consultation today. For a full list of my offerings please visit my website PaolaAtlason.live. For daily musings come see me on Instagram @PaolaAtlasonWelllness, or subscribe to my newsletter to receive practical self care tips and recipes, right in your inbox! Cheers, Paola

Today on the podcast we welcome Dr Perry Nickelston, a man who's work has profoundly changed my life. He's my teacher, a mentor and the first (and likely only) guy featured on The Live Journal. I'm ok bending my own rules since the techniques I've learned from him are also impacting my clients (mostly women's) lives. Perry Nickelston, DC, NKT, FMS, SFMA, is a Chiropractic Physician with primary focus on Performance Enhancement, Corrective Exercise, and Metabolic Fitness Nutrition and trained fromThe American College of Addictionology and Compulsive Disorders. He is an expert in myofascial, orthopedic, medical and trigger point soft tissue therapy. A member of the Board of Directors and Medical Staff Advisor for AIMLA (American Institute of Medical Laser Application). Dr. Perry teaches healthcare professionals all over the world how to successfully use Class IV Deep Tissue Laser Therapy in alleviating pain. Director of clinical protocols and training for LiteCure Medical Lasers specializing in Myofascial Laser treatments. -- Are you ready for your transformation? Do you want to feel energized, happy and free? Then let's chat! Schedule a Consultation today. For a full list of my offerings please visit my website PaolaAtlason.live. For daily musings come see me on Instagram @PaolaAtlasonWelllness, or subscribe to my newsletter to receive practical self care tips and recipes, right in your inbox!

Welcome back to Part 2 of Magic's interview with Dr. Perry Nickelston.  In this episode we explore the many different ways you can create health and wealth in your life and some of Dr. Perry's favorite tips.What he finds is that often people get stressed out that they'll be doing the exercises wrong, or breathing wrong, or eating wrong.  Dr. Perry's advice is that no matter what you're doing, make sure there is variety and variation.  Human bodies aren't meant to do and eat the same thing all the time.One of Dr. Perry's tips for overall health is The 4 Ms of Motion:Move more of yourself than you do now,More often than you do now,More ways than you do now,In more environments than you do now.Creating the awareness of how you are moving and nourishing your body will in itself create changes for the better.Perry Nickelston, DC, NKT, FMS, SFMA, is a Chiropractic Physician with primary focus on Performance Enhancement, Corrective Exercise, and Metabolic Fitness Nutrition and trained fromThe American College of Addictionology and Compulsive Disorders.Connect with Dr. Perry Nickelston:Online: https://www.stopchasingpain.com/On Facebook: https://www.facebook.com/officialstopchasingpainllcConnect with Magic:A Magical Life Podcast on Facebook: https://www.facebook.com/amagicallifepodcast/On Instagram: https://www.instagram.com/wholisticnaturalhealth/Online: https://wholisticnaturalhealth.com.auSupport the show (https://www.amazon.com/Stop-being-FAT-achieving-permanent-ebook/dp/B00PS9F9UO/ref=sr_1_3?dchild=1&keywords=stop+being+fat+love+yourself+skinny&qid=1627427882&sr=8-3)

Perry Nickelston, DC, NKT, FMS, SFMA, is a Chiropractic Physician with primary focus on Performance Enhancement, Corrective Exercise, and Metabolic Fitness Nutrition and trained fromThe American College of Addictionology and Compulsive Disorders.Magic has studied with Dr. Perry and her big question for him today is this: Why is the lymphatic system so dismissed?For this first part of the interview, Magic and Dr. Perry discuss the importance of the basics and fundamentals of health, how the mind behaves in regards to health, and how the simplest solution is usually the best one.  They'll also share the mystery of the toothbrush and how it can help take care of your body's filtration system.Connect with Dr. Perry Nickelston:Online: https://www.stopchasingpain.com/On Facebook: https://www.facebook.com/officialstopchasingpainllcConnect with Magic:A Magical Life Podcast on Facebook: https://www.facebook.com/amagicallifepodcast/On Instagram: https://www.instagram.com/wholisticnaturalhealth/Online: https://wholisticnaturalhealth.com.auSupport the show (https://www.amazon.com/Stop-being-FAT-achieving-permanent-ebook/dp/B00PS9F9UO/ref=sr_1_3?dchild=1&keywords=stop+being+fat+love+yourself+skinny&qid=1627427882&sr=8-3)

jon is joined by special guest Dr. Michelle Haslam; they discuss her time in the authoritarian group known as "new kadampa tradition", her background in psychology, and how and why people are drawn into destructive groups. links discussed in the video: the research of Miriam Anders on the cultic misuse of Buddhist teachings: https://www.mdpi.com/2077-1444/10/11/622/htm The Pema Chödrön Foundation: https://pemachodronfoundation.org the findings of the Australian Royal Commission on Institutional Responses to Child Sexual Abuse: https://www.childabuseroyalcommission.gov.au Michelle's YouTube channel: https://www.youtube.com/channel/UCDz-Wk0ykecFBgB7Pg31cVQ/videos and for help getting out of/surviving the NKT and other similar groups, Michelle's website is here: https://newkadampatraditionreport.org jon's paper, the Total Freedom Trap: https://www.cs.cmu.edu/~dst/Fishman/atack-freedom-trap.html Sir Ken Robinson's work: http://sirkenrobinson.com

In this episode of TrialSite News Podcast we speak with Dr. Theresa Deisher about supercharging the body's own natural immune response; a potential solution to global pandemics, no-option cancers, and auto-immunity. AVM Biotechnology's lead product, AVM0703, is based on a repurposed active ingredient (Dexamethasone) approved and in use for over 60 years. Originally being researched as a precursor conditioning agent to alleviate the side effects of chemotherapy, we discovered that significantly increasing the dose of AVM's purified version induced novel natural killer T-cells (NKT), supercharged cytotoxic T-cells, and supercharged dendritic cells. The combination of these three amplified immune cells mobilized by AVM0703 show promise in aggressive cancer models. NKT cells and cytotoxic T lymphocytes are by nature programmed to kill viruses and bacteria as well as cancer. The combination of these three mobilized supercharged immune cells should kill the COVID-19-causing virus (SARS CoV2) and induce long-term. These are cells which are not normally present in circulation and are uniquely induced by AVM0703. AVM received FDA IND permission to test our lead product AVM0703 for treatment of lymphoid malignancies. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has filed with the FDA for approval to proceed with clinical trials against this virus as well as Influenza virus which also causes deadly ARDS. With a global advisory team including experts in oncology, respiratory disease, and vaccines. Fine out more about Dr. Deisher and AVM  To read more from AVM News go here